Medical Technology firm Sky wins Kings Innovation Award for geko device breakthrough
The Geko™ device, a groundbreaking innovation in wound care technology, is making significant strides in the global market for chronic wound healing, particularly for difficult-to-heal venous leg ulcers (VLUs) and related conditions.
Recent clinical trials have demonstrated the device's effectiveness. A 2023 multicenter randomized trial published in the International Wound Journal showed that when combined with standard care, the Geko device more than doubled healing rates in hard-to-treat VLUs compared to standard care alone[1].
The device employs OnPulse™ neuromuscular electrostimulation technology, which activates the calf muscle pump, improving blood flow to the lower extremities. This enhanced circulation can promote wound healing and reduce edema, key factors in managing chronic wounds such as VLUs, diabetic foot ulcers, and pressure injuries[3].
The Geko device is gaining traction in professional healthcare settings. At events like WoundWISE Kitchener 2025, the device was highlighted alongside other advanced wound care technologies, showcasing its role in optimizing pressure injury prevention and exudate control through improved blood flow[3].
Aside from the Geko device, other innovative wound healing technologies, such as new composite nanofiber dressings with antibacterial and antioxidant properties, are also advancing healing outcomes[2]. However, the Geko device's unique mechanical mechanism addressing physiological blood flow sets it apart as a complementary and effective tool in the market.
The Geko device is designed for ease of use in both clinical and home settings, allowing patients to manage their care more independently. With FDA clearance, NICE guidance, and integration across NHS Trusts and international health systems, the company claims the Geko device is establishing a new standard in chronic wound management[4].
Clinicians are reporting an immediate reduction in pain associated with the use of the Geko device[5]. Patient-reported benefits are drawing attention in clinical settings due to the device's rapid effect on healing[6]. The number of prescriptions for the Geko device is increasing by over 60% quarter-over-quarter for the last 3 consecutive quarters[7].
Sky Medical Technology Ltd, a UK-based medical device innovator and manufacturer, has been awarded the King's Award for Enterprise in Innovation for their breakthrough wound care technology, the Geko device[8]. Fiona Young, Firstkind Wound Therapy Business Director, commented that the Geko device delivers real-world value clinically, operationally, and economically[9].
Real-world data from the UK Wound Care Registry supports the effectiveness of the Geko device[10]. As the device's adoption escalates across multiple NHS primary care clinics, it is clear that the Geko device is clinically validated, commercially active, and increasingly integrated into wound management protocols worldwide, particularly in the venous leg ulcer segment where vascular insufficiency is a primary concern[1][3].
The Geko device's impact is substantial in improving healing rates and patient quality of life in chronic wound care, addressing an unmet need with a clinically validated, non-invasive therapy[11]. With its rapid rate of adoption since its UK commercial launch in February 2024, the Geko device is poised to revolutionize chronic wound management.
[1] https://onlinelibrary.wiley.com/doi/abs/10.1111/iwj.13871 [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815969/ [3] https://www.woundcareadvisor.com/news/geko-device-for-venous-leg-ulcers-shows-promising-results-in-randomized-controlled-trial [4] https://www.sky-medical.com/news/geko-device-establishes-new-standard-in-chronic-wound-management [5] https://www.sky-medical.com/news/geko-device-delivers-immediate-pain-reduction-in-clinical-settings [6] https://www.sky-medical.com/news/geko-device-rapidly-accelerates-wound-healing-in-clinical-settings [7] https://www.sky-medical.com/news/geko-device-prescription-numbers-increase-by-over-60-quarter-over-quarter [8] https://www.gov.uk/government/news/uk-companies-honoured-in-the-kings-awards-for-enterprise [9] https://www.sky-medical.com/news/fiona-young-firstkind-wound-therapy-business-director-comments-on-geko-device [10] https://www.sky-medical.com/news/geko-device-supported-by-real-world-data-from-uk-wound-care-registry [11] https://www.sky-medical.com/news/geko-device-addresses-unmet-need-in-chronic-wound-management
- The Geko device, a technology rooted in science, is revolutionizing medical-conditions like venous leg ulcers by employing advanced technology like neuromuscular electrostimulation, thereby enhancing health-and-wellness for patients.
- With its innovative OnPulse technology, the Geko device, made by Sky Medical Technology Ltd, has been recognized with prestigious awards such as the King's Award for Enterprise in Innovation, showcasing its significant impact on medical plastics and patient care.
- In the realm of health-and-wellness and technology, the Geko device is not only improving wound healing outcomes for conditions such as diabetic foot ulcers and pressure injuries but is also reducing edema, making it a vital addition to professional healthcare settings.
